A Seattle biotech built on University of Washington research has won a $245 million patent judgment against Guardant Health over DNA sequencing technology, with the court also ordering ongoing royalties through 2033. Read More
Developing the next generation of RNA- and DNA-based medicines requires a level of precision that many existing research tools can’t provide. Vancouver, B.C.-based startup ScopeSys aims to change that. Read More